Letter from the Editor

Dear Reader,

Welcome to Medicom's report of this year's ESMO Annual Congress!

Again, as in previous years: quite some practice changing studies.
Remarkably, in the field of ovarian cancer, there are three parallel studies providing evidence for clinically relevant benefit of targeted agents (PARP inhibitors) – as well as the predictive factors: BRCA as an already established – and HRD, a “BRCA-ness” predictive factor well established through the 3 studies, broadening the patient group identifiable as the most benefitting.

Read the exciting results presented by Julien Taieb: are we getting closer to a true predictive marker in stage II colorectal cancer in detecting circulating tumor DNA after primary surgery? Can we stratify adjuvant treatment according to ctDNA?

Will we eventually treat all our patients with advanced non-small cell lung cancer without chemotherapy?

…just some examples. I'll stop here and let you have a closer look at our report.

Medical Oncology – truly evolving!

Yours, sincerely

Stefan Rauh

 

Biography

Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is Chair of the ESMO Practicing Oncologist’s Working Group since 2015, member of the ESMO Quality Task Force, extended member of the ESMO Public Policy Committee, Assistant Editor of ESMO Cancer Horizons, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.

Conflict of Interest Statement: Nothing to declare



Posted on 26 November 201925 February 2021